PDA-002

BIOLOGICAL4 trials

Sponsors

Celularity Incorporated

Conditions

Diabetic FootDiabetic Foot UlcerDiabetic NephropathiesPeripheral Arterial DiseasePeripheral Nervous System Diseases

Phase 1

Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers

CompletedNCT01859117

Celularity IncorporatedDiabetic Foot Ulcer, Peripheral Arterial Disease

Start: 2013-05-23End: 2017-03-14Updated: 2026-06-04

Phase 2

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

TerminatedNCT02264288

Celularity IncorporatedDiabetic Foot, Peripheral Arterial Disease

Start: 2014-10-23End: 2018-02-27Updated: 2026-06-12

Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

WithdrawnNCT02460081

Celularity IncorporatedDiabetic Foot, Peripheral Arterial Disease

Start: 2015-06-01End: 2016-01-06Updated: 2026-04-29

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

CompletedNCT02552277

Celularity IncorporatedDiabetic Nephropathies, Peripheral Nervous System Diseases

Start: 2015-10-27End: 2017-10-30Updated: 2022-02-02